Matt Davies

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Venues

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)

Matt Davies.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Matt Davies